Objective: The response to some antihypertensive therapies may be affected by age.
Valsartan is a potent, highly selective angiotensin II receptor blocker used to treat …

Many patients with hypertension, especially those at increased risk because of additional
cardiovascular risk factors, require treatment with more than one antihypertensive agent to …

Early combination therapy is increasingly recommended in hypertension management
because of increased risk of adverse effects with high-dose monotherapy. However, this risk …

The pharmacological efficacy of various monotherapy, single pill, and combination therapies
of the angiotensin II receptor blocker valsartan have been established, mainly through …

Aim. Sacubitril‐valsartan has proven beneficial in heart failure with reduced ejection fraction.
Guidelines recommend initiating half‐dose sacubitril‐valsartan before up‐titration even to …

Background Hypertension is a leading cause of death worldwide, and a major public health
problem in Canada. Despite treatment guidelines and availability of therapies for blood …

Despite the strong clinical benefits of sacubitril-valsartan in HFrEF (3)(4)(5)(6), uncertainty
regarding the underlying mechanisms of ARNi remains. Up to date, most mechanistic and …

Introduction Sacubitril/Valsartan is a novel therapy in the treatment of heart failure with
reduced ejection fraction, demonstrating a lower cardiovascular mortality and heart failure …

Discussion and Conclusions: An answer to this problem appears now offered by a recent
class of antihypertensive agents, the angiotensin II receptor blockers (ARBs). Among them …